CYP2D6, noribogaine, GDNF, hERG — the molecular detail behind a single ibogaine session.

Ibogaine is a multi-receptor compound — it binds NMDA receptors (antagonist), kappa- and mu-opioid receptors, sigma-2 receptors, serotonin transporters (reuptake inhibition), and α3β4 nicotinic acetylcholine receptors (antagonist). No single receptor explains the effect; it is the combination plus the long-acting metabolite noribogaine, plus increased GDNF and BDNF expression, that produces the addiction-medicine-grade reset.

Noribogaine is the long-acting metabolite produced by CYP2D6-mediated O-demethylation of ibogaine. While ibogaine has a half-life of ~7 hours, noribogaine persists 28-49 hours and continues acting on serotonin reuptake and kappa-opioid receptors. The clarity, calm, and reduced craving patients describe in the post-acute window is largely noribogaine pharmacology.

CYP2D6 is the primary enzyme converting ibogaine to noribogaine. About 7% of the population are CYP2D6 poor metabolizers — they produce less noribogaine and have higher peak ibogaine levels (more cardiac risk). About 1-2% are ultrarapid metabolizers — they convert ibogaine quickly with reduced peak. Strong CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion, quinidine) functionally convert any patient into a poor metabolizer. We genotype or phenotype when indicated.

Ibogaine inhibits the hERG (Kv11.1) potassium channel, delaying ventricular repolarization. This shows up on EKG as a prolonged QT interval. Severe QTc prolongation increases the risk of torsades de pointes, a potentially fatal arrhythmia. This is why every patient gets a baseline 12-lead EKG, electrolyte normalization (K+, Mg2+), continuous telemetry during treatment, and a meticulous medication review — and why we exclude patients with structural heart disease, congenital long-QT syndrome, or recent cardiac events.

Neuroplasticity is the brain's ability to change its structural and functional connections. Ibogaine and noribogaine increase expression of GDNF (glial-cell-derived neurotrophic factor) and BDNF (brain-derived neurotrophic factor) — molecules that promote the survival, differentiation, and synaptic remodeling of dopamine neurons in the ventral tegmental area and serotonergic neurons throughout the brain. This is the molecular basis for why a single ibogaine session can produce changes that persist months — synaptic structure has been physically remodeled.

The evidence base is strongest for opioid use disorder — observational cohort studies (Brown 2014, Mash 2016), open-label trials (Davis 2017), and the Stanford TBI/depression trial (Cherian, Williams 2024) all showing meaningful effects on craving, withdrawal, mood, and cognition. The evidence is emerging for PTSD, depression, and TBI, and weaker for stimulant addiction. Randomized controlled trials in opioid use disorder are still limited because Schedule I status restricts US research; this is changing — Kentucky, Vermont, and Texas have allocated research funds, and DEA scheduling is being actively challenged.

Ibogaine was scheduled in 1970 alongside other psychedelics, before its anti-addictive properties were clinically characterized. Schedule I status restricts US research and prohibits clinical use, which is why patients travel to Mexico or other regulated jurisdictions for treatment. The legal status of ibogaine treatment outside the US is country-specific — Mexico permits it as an experimental therapy in licensed medical facilities. We operate fully within Mexican medical-regulatory frameworks. Read more at /ibogaine-legal-status.

Yes — and this is an active research area. Some companies (Atai, MindMed, DemeRx) are developing pure noribogaine as a separate therapeutic, hypothesizing that it may retain some of the anti-craving effect with less acute cardiac risk. The trade-off is that noribogaine alone may lack the deep introspective trajectory associated with ibogaine's NMDA antagonism. Current clinical practice still uses ibogaine HCl, which produces both compounds in the patient via CYP2D6 metabolism.